George Washington (GW) Cancer Center Selected as First Global Site for Regeneron High Risk Cutaneous Cell Cancer

George Washington (GW) Cancer Center Selected as First Global Site for Regeneron High Risk Cutaneous Cell Cancer

The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous cell carcinoma. GW Cancer Center was selected for this Regeneron-sponsored Phase II...

Pin It on Pinterest